All In Biotech

Drug Trial Radar · NCT05650879

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jul 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

198

Planned (sponsor's estimate)

Start

Mar 20, 2023

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Enliven TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer.

Conditions

  • HER2 Mutant Non-small Cell Lung Cancer
  • HER2-positive Metastatic Breast Cancer
  • HER2 Gene Mutation
  • HER2 Amplification

Interventions

  • ELVN-002Drug

    capsule

  • Fam-Trastuzumab Deruxtecan-NxkiDrug

    intravenous

  • Trastuzumab emtansineDrug

    intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities in Phase 1a monotherapyTime frame: 21 days
  2. Incidence of adverse events in Phase 1a monotherapyTime frame: 24 months
  3. incidence of laboratory abnormalities in Phase 1a monotherapyTime frame: 24 months
  4. incidence of ECG abnormalities in Phase 1a monotherapyTime frame: 24 months
  5. incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd)Time frame: 42 days
  6. Incidence of adverse events in Phase 1a combination with T-DXdTime frame: 24 months
  7. incidence of laboratory abnormalities in Phase 1a combination with T-DXdTime frame: 24 months
  8. incidence of ECG abnormalities in Phase 1a combination with T-DXdTime frame: 24 months
  9. incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1)Time frame: 42 days
  10. Incidence of adverse events in Phase 1a combination with T-DM1Time frame: 24 months
  11. incidence of laboratory abnormalities in Phase 1a combination with T-DM1Time frame: 24 months
  12. incidence of ECG abnormalities in Phase 1a combination with T-DM1Time frame: 24 months
  13. Incidence of adverse events in Phase 1b monotherapyTime frame: 24 months
  14. incidence of laboratory abnormalities in Phase 1b monotherapyTime frame: 24 months
  15. incidence of ECG abnormalities in Phase 1b monotherapyTime frame: 24 months

Locations

39 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Colorado - Anschutz Medical Campus - PPDS

    Aurora, Colorado

  • Advent Health Orlando

    Orlando, Florida

  • BRCR Medical Center Inc

    Plantation, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • NEXT/Virginia Cancer Specialists

    Fairfax, Virginia

  • Blacktown Hospital

    Darlinghurst, Australia

  • Macquarie University Hospital

    Westmead, New South Wales, Australia

  • Linear Clinical Research Limited

    Nedlands, Western Australia, Australia

  • Centre Georges François Leclerc

    Dijon, France

  • Centre Léon Berard

    Lyon, France

  • Institut Gustave Roussy (IGR)

    Villejuif, France

  • Hôpital de la Timone Centre d'essais en cancérologie de Marseille (CEPCM-CLIPP)

    Marseille, Bouches-du-Rhône, France

  • Hôpital Pontchaillou

    Rennes, Brittany Region, France

  • Centre Francois Baclesse

    Caen, Calvados, France

  • EDOG - Institut Bergonie - PPDS

    Bordeaux, Gironde, France

  • Fondazione Policlinico Universitario A. Gemelli

    Roma, Italy

  • Unità Operativa Oncologia medica ed Ematologia

    Rozzano, Italy

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Lombardy, Italy

  • Fondazione del Piemonte per l'Oncologia (IRCCS)

    Candiolo, Piedmont, Italy

  • SOC Oncologia Medica e dei Tumori lmmunocorrelati, Centro Di Riferimento Oncologico Di Aviano (CRO) IRCCS

    Aviano, Pordenone, Italy

  • Azienda Ospedaliero Universitaria delle Marche

    Ancona, The Marches, Italy

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Severence Hospital, Yonsei University

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • The Catholic University of Korea, St. Vincent's Hospital

    Suwon, Gyeonggido, South Korea

  • START Barcelona Hospital HM Nou Delfos

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebrón

    Barcelona, Spain

  • lnstitut Catala d'Oncologia (ICO) L'Hospitalet, Servicio de Oncologia Medica

    L'Hospitalet de Llobregat, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Fundación Instituto Valenciano de Oncología

    Valencia, Spain

  • Hospital Universitari i Politècnic La Fe

    Valencia, Spain

  • Hospital Universitari Arnau de Vilanova

    Lleida, Lleida, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Sevilla, Spain

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • National Chen Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.